Canada Spends Logo

Explore our Budget 2026 analysis

Other transfer or payment: SIF Stream2- Growth

Entos Pharmaceuticals Inc.

$62,000,000.00

Innovation and Biomanufacturing Centre project

FY 2024-25 · 2025-02-13

Summary
This project will support the establishment of an innovation research and development (R&D) centre and a commercial scale, good manufacturing practices (GMP) manufacturing facility in Edmonton, Alberta for the production of novel genetic medicines.
Program
SIF Stream2- Growth
Location
Edmonton, Alberta, Canada
Recipient Type
For-profit organization
Business Number
816561112
Type
Other transfer or payment
Source
Proactive Disclosure - Grants and Contributions

As published

Additional Information
This is a partially unconditionally repayable contribution.
Additional Information (French)
Il s’agit d’une contribution partiellement et inconditionnellement remboursable.
Agreement End Date
2047-06-01
Agreement Number
819748
Agreement Start Date
2025-02-13
Agreement Title
Innovation and Biomanufacturing Centre project
Agreement Title (French)
Projet du Centre d'innovation et de bioproduction
Agreement Type
Other transfer payment
Agreement Value
$62,000,000.00
Amendment Number
0
Description
This project will support the establishment of an innovation research and development (R&D) centre and a commercial scale, good manufacturing practices (GMP) manufacturing facility in Edmonton, Alberta for the production of novel genetic medicines.
Description (French)
Ce projet soutiendra l’établissement d’un centre de recherche et développement (R&D) en innovation ainsi que d’une installation de production à l’échelle commerciale, conforme aux bonnes pratiques de fabrication (BPF), à Edmonton, en Alberta, pour la production de médicaments génétiques novateurs.
Expected Results
This investment will help strengthen pandemic preparedness and increase domestic biomanufacturing capacity of genetic medicines used to help treat diseases, including cancers, infectious diseases, and neurodegenerative diseases.
Expected Results (French)
Cet investissement contribuera à renforcer la préparation aux pandémies et à augmenter la capacité de bioproduction nationale de médicaments génétiques utilisés pour traiter des maladies, notamment le cancer, les maladies infectieuses et les maladies neurodégénératives.
Federal Riding
Edmonton Centre
Federal Riding (French)
Edmonton-Centre
Federal Riding Number
48014
NAICS Code
325410
Organization Code
ic
Organization
Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada
Program Name
SIF Stream2- Growth
Program Name (French)
FIS Volet 2- Croissance
Program Purpose
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
Program Purpose (French)
-favoriser les activités de R-D qui accéléreront le transfert de la technologie et la commercialisation de produits, de processus et de services novateurs ;-faciliter la croissance et l'expansion des entreprises au Canada ;-attirer et conserver des investissements de grande envergure au Canada ; et-faire progresser la recherche industrielle, le développement et la démonstration de technologies grâce à la collaboration entre les universitaires, les organisations à but non lucratif et le secteur privé.
Recipient Business Number
816561112
Recipient City
Edmonton
Recipient Country
CA
Recipient Legal Name
Entos Pharmaceuticals Inc.
Recipient Operating Name
Entos Pharmaceuticals Inc.
Recipient Postal Code
T5J4P6
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
033-2024-2025-Q4-819748